Smoking cessation: lessons learned from clinical trial evidence

Reid, Robert D.; Quinlan, B.; Riley, Dana L.; Pipe, Andrew

doi:10.1097/hco.0b013e328236740a

Cited by 25 publications

(18 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17 Treatment of smoking is the standard of care for CV risk reduction, but interventions without follow-up are not effective, especially for adult smokers. 18 Therefore, long-term management is needed, as in the standard treatments for hypertension, hyperlipidemia and metabolic syndrome.…”

Section: Discussionmentioning

confidence: 99%

A Randomized Controlled Open Comparative Trial of Varenicline vs Nicotine Patch in Adult Smokers - Efficacy, Safety and Withdrawal Symptoms (The VN-SEESAW Study) -

Tsukahara

Noda

Saku

2010

Circ J

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

A Randomized Controlled Open Comparative Trial of Varenicline vs Nicotine Patch in Adult Smokers - Efficacy, Safety and Withdrawal Symptoms (The VN-SEESAW Study) -

Tsukahara

Noda

Saku

2010

Circ J

View full text Add to dashboard Cite

“…Health centres that have made smoking cessation programs a part of the institution's mission to provide quality care and outreach also become a driving force for smokers' acceptance of smoking cessation support 4.5.2 Restraining Forces: Patients' Barriers to Change Behavioural patterns can influence patients' views of the importance of smoking to their lifestyle. Many smokers not only enjoy the social aspects of being with other smokers or make the association of smoking with activities they enjoy, they also believe smoking improves their ability to cope with stress, anxiety and/or boredom (Reid et al, 2007a). As these beliefs are tied to a smoker's personal identity, and reflect his or her established way to deal with difficult issues, smoking cessation encompasses more than the physical obstacle of nicotine dependence.…”

Section: Drivers: Patients' Motivation To Change the Current Situationmentioning

confidence: 99%

Organizational Development: Driving Forces and Barriers Encountered when Implementing Smoking Cessation Programs

Wardley¹,

Mullen²,

Bélanger³

et al. 2014

IJBA

View full text Add to dashboard Cite

Background: Globally, use of tobacco has been identified as one of the greatest risk factors for mortality and the leading cause of preventable death. The purpose of this paper was to apply the lens of a business change model to the healthcare sector to better understand forces driving the implementation of smoking cessation programs and to identify ways to overcome resistance to changes in smoking behaviour and protocols.

show abstract

“…Furthermore, the availability of statins in clinical practice has been a revolution because physicians now have powerful tools to substantially lower low-density lipoprotein (LDL)-cholesterol concentrations, thereby reducing CVD events and related mortality (10,11). In addition, although smoking remains prevalent in some subgroups and sometimes is used as a means for body weight control in teenage girls, public policies and laws now in place have contributed to create an environment not permissive to, and certainly not comfortable for, smokers (8,12), which has had a very significant impact on the prevalence of smoking in Canada. Thus, the prevalence of smoking and of untreated elevated LDL-cholesterol and hypertension has decreased markedly over the past two decades.…”

Section: Modifiable Cvd Risk Factors: An Evolving Mosaicmentioning

confidence: 99%

“…For instance, the prevalence of smoking has decreased over the past few decades (8). In addition, hypertension is now aggressively detected and managed with a comprehensive pharmacological arsenal and treatment is associated with clinical benefits (9).…”

Section: Modifiable Cvd Risk Factors: An Evolving Mosaicmentioning

confidence: 99%

Abdominal obesity: The cholesterol of the 21st century?

Després¹,

Arsenault

Côté

et al. 2008

Canadian Journal of Cardiology

108

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is a leading cause of morbidity and death in many countries worldwide. With the help of epidemiological, metabolic and clinical studies conducted over the past decades, the key factors contributing to the development of CVD have been identified. In this regard, several modifiable (hypertension, smoking, elevated cholesterol or lowdensity lipoprotein-cholesterol concentrations, reduced levels of highdensity lipoprotein-cholesterol, type 2 diabetes) and nonmodifiable (age, sex, genetic predisposition) CVD risk factors have been recognized. Although better acute care and chronic pharmacological management have contributed to reduce CVD mortality, CVD morbidity remains very high. It has been proposed that this situation could be the consequence of the evolving landscape of CVD risk factors, which include, among others, poor nutritional habits and a reduction in physical activity contributing to the epidemic of obesity sweeping the world. However, obesity is heterogeneous both in terms of its etiology and its metabolic complications. Body fat distribution, especially visceral adipose tissue accumulation, has been found to be a major correlate of a cluster of diabetogenic and atherogenic abnormalities that has been described as the metabolic syndrome. The importance of abdominal obesity in association with the development of CVD and type 2 diabetes has been recognized in several studies, beyond the contribution of overall obesity. Additional evidence also suggests that the CVD risk related to the hyperglycemic state observed in subjects with the metabolic syndrome or type 2 diabetes is largely explained by the high prevalence of the metabolic complications of abdominal obesity. Although the presence of the metabolic syndrome clearly increases CVD risk, its clinical diagnosis is not sufficient to classify a patient at high risk for a cardiovascular event because attention must also be paid to the presence of traditional risk factors in the calculation of global CVD risk. The additional information provided by the metabolic syndrome to the risk attributed to traditional risk factors in the calculation of global CVD risk has been defined as global cardiometabolic risk. The fight against abdominal obesity as a major cause of CVD morbidity and mortality will require major societal changes and the involvement of dieticians, kinesiologists and behaviour modification specialists in clinical practice to reshape our physical activity and dietary habits. Finally, the early prevention of overweight/obesity/abdominal obesity in children, starting as early as conception, and the identification of key drivers of unhealthy nutritional and sedentary behaviours are the cornerstone of a successful comprehensive plan to fight CVD morbidity. Les maladies cardiovasculaires (MCV) représentent toujours la première cause de morbidité et mortalité dans plusieurs pays. Les nombreuses études épidémiologiques, métaboliques et cliniques réalisées au cours des dernières années ont permis l'identification des principaux ...

show abstract

Smoking cessation: lessons learned from clinical trial evidence

Cited by 25 publications

References 47 publications

A Randomized Controlled Open Comparative Trial of Varenicline vs Nicotine Patch in Adult Smokers - Efficacy, Safety and Withdrawal Symptoms (The VN-SEESAW Study) -

A Randomized Controlled Open Comparative Trial of Varenicline vs Nicotine Patch in Adult Smokers - Efficacy, Safety and Withdrawal Symptoms (The VN-SEESAW Study) -

Organizational Development: Driving Forces and Barriers Encountered when Implementing Smoking Cessation Programs

Abdominal obesity: The cholesterol of the 21st century?

Contact Info

Product

Resources

About